<DOC>
	<DOCNO>NCT01145625</DOCNO>
	<brief_summary>This year-long clinical trial evaluate effectiveness safety woman Female Pattern Hair Loss ( FPHL ) , compare new 5 % minoxidil topical foam ( MTF ) formulation apply day versus 2 % minoxidil topical solution ( MTS ) apply twice day . This clinical trial us objective measurement call Target Area Hair Count ( TAHC ) evaluate change number hair area examine use product 24 week ( also use product 12 Weeks 52 week ) . This trial determine benefit use either study product outweigh risk .</brief_summary>
	<brief_title>Clinical Trial Females With Female Pattern Hair Loss</brief_title>
	<detailed_description>This phase 3 , two-arm , randomize , active-controlled , multi-center , 52-week , parallel design trial evaluate efficacy safety woman Female Pattern Hair Loss ( FPHL ) , compare new 5 % minoxidil topical foam ( MTF ) formulation versus 2 % minoxidil topical solution ( MTS ) formulation . This clinical trial design compare risk/benefit profile 5 % MTF formulation apply day versus 2 % MTS apply twice day ( BID ) , use objective efficacy measure safety assessment . Study center screen sufficient number participant minimum 300 female participant FPHL enrol , ensure 270 complete . There least 16 participant enrol per center multiple center locate across US globally . Approximately 300 participant randomly assign 1:1 ratio use either 5 % MTF 2 % MTS , 52 week efficacy safety evaluation . Participants meet inclusion criterion randomly assign order enrollment site . The signing informed consent assignment participant number subject shall constitute enrollment . During trial follow enrollment Baseline , participant return study site regular interval safety assessment , adverse event monitoring , compliance assessment . At Week 12 , 24 , Week 52 visit TAHC evaluate efficacy analysis .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<criteria>female , age 18 old general good health exhibit female pattern hair loss sign date informed consent document agree use adequate method birth control ; childbearing potential show negative urine pregnancy test Screening Visit willing maintain hair style , hair color , hair regimen throughout study willing able comply schedule visit , treatment plan , laboratory test trial procedure hypersensitivity study product , ingredient study product know allergy hair dye , hair dye component clinically relevant history hypotension untreated uncontrolled hypertension pregnant , plan pregnancy nurse child history hair transplant currently use hair weave nonbreathable wig dermatologic disorder scalp require chronic use medication control type history hair loss enrol investigational medication ( drug ) study currently , within last 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Female Pattern Baldness</keyword>
</DOC>